Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

被引：22

作者：

Qualls, David A.

Lambert, Nicholas ^{[1
,2
]}

Caimi, Paolo F. ^{[3
]}

Merrill, Mwanasha ^{[4
]}

Pullarkat, Priyanka ^{[5
]}

Godby, Richard C. ^{[6
]}

Bond, David A. ^{[6
]}

Wehmeyer, Graham T. ^{[9
,10
]}

Romancik, Jason ^{[11
]}

Amoozgar, Behzad ^{[12
]}

Leslie, Lori ^{[11
]}

Nastoupil, Loretta J. ^{[1
,13
,14
]}

Crombie, Jennifer L. ^{[4
]}

Abramson, Jeremy S. ^{[4
]}

Khurana, Arushi ^{[6
]}

Nowakowski, Grzegorz S. ^{[5
]}

Maddocks, Kami ^{[7
,8
]}

Rutherford, Sarah C. ^{[9
,10
]}

Kahl, Brad ^{[12
]}

Okwali, Michelle ^{[1
]}

Buege, Michael J. ^{[1
]}

Seshan, Venkatraman ^{[1
]}

Batlevi, Connie L. ^{[1
]}

Salles, Gilles ^{[1
,15
,16
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Malignancies, New York, NY 10065 USA

[2] Baylor Coll Med, Dept Med, Houston, TX USA

[3] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[5] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA USA

[6] Mayo Clin, Div Hematol & Oncol, Dept Internal Med, Rochester, MN USA

[7] Ohio State Univ, James Canc Hosp, Columbus, OH USA

[8] Ohio State Univ, Solove Res Inst, Columbus, OH USA

[9] Weill Cornell Med, Dept Med, Meyer Canc Ctr, New York, NY USA

[10] New York Presbyterian Hosp, New York, NY USA

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[12] Washington Univ, Sch Med, Dept Med, St Louis, MO USA

[13] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[15] Weill Cornell Med Coll, New York, NY 10065 USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

BLOOD | 2023年 / 142卷 / 26期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1182/blood.2023021274

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL. © 2023 The American Society of Hematology

引用

页码：2327 / 2331

页数：5

共 50 条

[41] Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
Iacoboni, Gloria
Villacampa, Guillermo
Martinez-Cibrian, Nuria
Bailen, Rebeca
Lopez Corral, Lucia
Sanchez, Jose M.
Guerreiro, Manuel
Carolina Caballero, Ana
Mussetti, Alberto
Sancho, Juan-Manuel
Hernani, Rafael
Abrisqueta, Pau
Solano, Carlos
Sureda, Anna
Briones, Javier
Martin Garcia-Sancho, Alejandro
Kwon, Mi
Luis Reguera-Ortega, Juan
Barba, Pere
CANCER MEDICINE, 2021, 10 (10): : 3214 - 3223
[42] Racial and ethnic representation in large B-cell lymphoma trials and real-world databases
Munoz, Javier
Mutebi, Alex
Wang, Tongsheng
Zhang, Guihua
Yu, Junhua
He, Jing
Chibber, Anindit
Kamalakar, Rajesh
Jun, Monika P.
Adejumo, Kelechi
Yang, Shibing
Kalsekar, Anupama
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Iacoboni, Gloria
Iraola-Truchuelo, Josu
Martinez-Cibrian, Nuria
Bailen, Rebeca
Corral, Lucia Lopez
Sanchez, Jose M.
Gonzalez, Ana Carolina Carolina Caballero
Mussetti, Alberto
Sancho, Juan-Manuel
Hernani, Rafael
Solano, Carlos
Balari, Anna Sureda
Briones, Javier
Garcia-Sancho, Alejandro Martin
Kwon, Mi
Reguera, Juan Luis
Barba, Pere
BLOOD, 2020, 136
[44] Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
Lee, Yong-Pyo
Hong, Jung Yong
Yoon, Sang Eun
Cho, Junhun
Shim, Joon-Ho
Bang, Yeonghak
Kim, Won Seog
Kim, Seok Jin
CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4241 - 4250
[45] Real-world clinical features and survival outcomes in diffuse large B-cell lymphoma patients with hepatitis B virus infection
Yang, Wanxi
Zhao, Xue
Ma, Hongbing
Xu, Caigang
INFECTIOUS AGENTS AND CANCER, 2024, 19 (01):
[46] RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Rodgers, Thomas
Zinzani, Pier Luigi
Marino, Dario
Frezzato, Maurizio
Barbui, Anna Maria
Castellino, Claudia
Meli, Erika
Conconi, Annarita
Cascavilla, Nicola
Cavallo, Federica
Fowler, Nathan H.
Feinberg, Bruce
Tillmanns, Sascha
Parche, Stephan
Fingerle-Rowson, Gunter
Winderlich, Mark
Ambarkhane, Sumeet
Salles, Gilles
Nowakowski, Grzegorz
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S266
[47] Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
Charanpreet Singh
Aditya Jandial
Arihant Jain
Deepesh Lad
Alka Khadwal
Rajender Basher
Amanjit Bal
Pankaj Malhotra
Gaurav Prakash
Indian Journal of Hematology and Blood Transfusion, 2024, 40 : 231 - 236
[48] Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
Singh, Charanpreet
Jandial, Aditya
Jain, Arihant
Lad, Deepesh
Khadwal, Alka
Basher, Rajender
Bal, Amanjit
Malhotra, Pankaj
Prakash, Gaurav
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (02) : 231 - 236
[49] Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States
Sawas, Ahmed
Lau, Constance
Thomson, Michael
Maignan, Kathleen
BLOOD, 2020, 136
[50] Real-world treatment patterns and outcomes in Japanese patients with large B-cell lymphoma after two systemic therapies
Liao, L.
Chhibber, A.
Zhang, G.
Kim, J.
Keshishian, A.
Chung, S.
Shrestha, S.
Ando, H.
Takaura, K.
Sakai, M.
Mutebi, A.
ANNALS OF ONCOLOGY, 2024, 35 : S1338 - S1338

← 1 2 3 4 5 →